MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO)*
Organization & Developments: Agios
Parents
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO)*
Children
*Agios has built a novel discovery engine centered on cancer metabolism.
*Discovering drugs intended to block metabolic enzymes that nourish tumors.
*The company's capabilities integrate cutting-edge techniques in metabolomics, biology, genetics, biochemistry and bioinformatics.
2010: Now has the largest research facility dedicated to the field of cancer drug metabolism (2010)
2014: Agios stock soars on preliminary blood cancer data_bizjournals
2016: Development of Second PKR Activator AG-519 Discontinued Following FDA Feedback -_ News Release- Agios
2017: Agios Pharmaceuticals: Updates To Thesis And A Look Toward 2018 - Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
2018: Agios Pharma Notches Another FDA Approval Under Its Belt For Rare Cancer Treatment_seekingalpha.com
2020: Agios: A Look At TIBSOVO In CC Patients
2020: Agios: A Targeted Pharmaceutical Stairway To Value_seekingalpha.com
2021: Agios A Buy For Rare Disease Focus, Stock Buyback
2021: Agios: Back To The Lab
2022: Agios Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Agios Pharmaceuticals: A Big Year On The Horizon_ seekingalpha.com
2024: Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
2024: Agios Is A Gem, But It Will Need Patience (Rating Upgrade)_ seekingalpha.com
2024: Agios Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Agios Pharmaceuticals: A Long Overdue Follow Up
2024: Agios Pharmaceuticals: Strong Thalassemia Data Makes A Tempting Bull Case_seekingalpha.com
2024: Agios Pharmaceuticals' SWOT analysis: promising pipeline, cash boost fuel stock outlook
2024: Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment_seekingalpha
2025: Agios Pharmaceuticals: A More Compelling Valuation
2025: Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision
2025: Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Jumps
*Key People: Agios
Finance & Acquisition: Agios